Home Newsfeeds Keybanc Maintains Overweight on Broadcom, Raises Price Target to $720

Keybanc Maintains Overweight on Broadcom, Raises Price Target to $720

Keybanc analyst John Vinh maintains Broadcom (NASDAQ:AVGO) with a Overweight and raises the price target from $700 to $720.

byBenzinga Newsdesk

March 3, 2023

1 minute read

Keybanc analyst John Vinh maintains Broadcom (NASDAQ:AVGO) with a Overweight and raises the price target from $700 to $720.

News

Teladoc Health Reaches 50M Visit Milestone Visits By The Company’s Global Network Of Clinicians

By Benzinga Newsdesk

November 15, 2:02 PM

Teladoc Health (NYSE:TDOC), the global leader in whole-person virtual care, announced today that it has surpassed 50 million visits delivered by the company's global network of clinicians. This milestone is in

TDOC

Chardan Capital Initiates Coverage On Anixa Biosciences with Buy Rating, Announces Price Target of $8

By Benzinga Newsdesk

December 23, 6:39 AM

Chardan Capital analyst Matthew Barcus initiates coverage on Anixa Biosciences (NASDAQ:ANIX) with a Buy rating and announces Price Target of $8.

ANIX

BAMF Health And GE HealthCare Collaborate To Enable Sustainable And Scalable Solutions For Growth In Theranostics; Expanding The Reach Of Care For Cancer And Other Disease States

By Benzinga Newsdesk

November 13, 11:01 AM

Long-term relationship will focus on the potential for new advancements to expand patient and clinician access and transform the approach to discovery, diagnosis, and treatment of cancer and other disease states.As

GEHC

Ultralife Q4 Sales $36.11M Miss $37.00M Estimate

By Benzinga Newsdesk

March 2, 8:09 AM

Ultralife (NASDAQ:ULBI) reported quarterly sales of $36.11 million which missed the analyst consensus estimate of $37.00 million by 2.41 percent. This is a 51.95 percent increase over sales of $23.76 million the same

ULBI

Keybanc Maintains Overweight on Broadcom, Raises Price Target to $720

Related Posts

Teladoc Health Reaches 50M Visit Milestone Visits By The Company’s Global Network Of Clinicians

Chardan Capital Initiates Coverage On Anixa Biosciences with Buy Rating, Announces Price Target of $8

BAMF Health And GE HealthCare Collaborate To Enable Sustainable And Scalable Solutions For Growth In Theranostics; Expanding The Reach Of Care For Cancer And Other Disease States

Ultralife Q4 Sales $36.11M Miss $37.00M Estimate